Merrill J. Egorin, M.D., is co-director of the molecular therapeutics/drug discovery program at the University of Pittsburgh Cancer Institute (UPCI). Dr. Egorin also is a professor of medicine and pharmacology at the University of Pittsburgh School of Medicine.
Dr. Egorin's research focuses on rational development and application of antineoplastic agents. He serves as principal investigator on a National Cancer Institute-funded contract evaluating the pharmacokinetics, metabolism and pharmacodynamics of antitumor agents being considered for clinical trials and is the co-principal investigator of a National Cancer Institute-funded cooperative agreement for conducting Phase I studies at UPCI. Key concepts regularly addressed in Dr. Egorin's research involve the pharmacokinetic and pharmacodynamic relationships of investigational and licensed antineoplastic agents and how those relationships can be assessed and modeled.
Dr. Egorin received his medical degree and training in internal medicine from the Johns Hopkins University School of Medicine and Hospital. Early in his career, he joined the Baltimore Cancer Research Center, then part of the National Cancer Institute. In 1981, he became a staff physician at the University of Maryland Hospital, where he rose to the position of professor of medicine, pharmacology and experimental therapeutics and oncology. Dr. Egorin was recruited to UPCI in 1998 to lead its clinical and preclinical pharmacology activities.
Dr. Egorin’s professional affiliations include a fellowship in the American College of Physicians and memberships in the American Association for Cancer Research, the American Society for Clinical Oncology, the American Society for Clinical Pharmacology and Therapeutics and the American Society for Pharmacology and Experimental Therapeutics. He serves on the editorial boards of several medical journals and is editor-in-chief of Cancer Chemotherapy and Pharmacology. Dr. Egorin has authored or co-authored numerous book chapters and more than 175 articles in peer-reviewed journals.